MA50080A - Méthodes d'utilisation du dantrolène pour traiter l'exposition à un agent neurotoxique - Google Patents
Méthodes d'utilisation du dantrolène pour traiter l'exposition à un agent neurotoxiqueInfo
- Publication number
- MA50080A MA50080A MA050080A MA50080A MA50080A MA 50080 A MA50080 A MA 50080A MA 050080 A MA050080 A MA 050080A MA 50080 A MA50080 A MA 50080A MA 50080 A MA50080 A MA 50080A
- Authority
- MA
- Morocco
- Prior art keywords
- dantrolene
- methods
- neurotoxic agent
- treat exposure
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762554049P | 2017-09-05 | 2017-09-05 | |
| US201862674406P | 2018-05-21 | 2018-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50080A true MA50080A (fr) | 2020-07-15 |
Family
ID=63708449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050080A MA50080A (fr) | 2017-09-05 | 2018-09-05 | Méthodes d'utilisation du dantrolène pour traiter l'exposition à un agent neurotoxique |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20200383954A1 (https=) |
| EP (1) | EP3678659B1 (https=) |
| JP (2) | JP2020532555A (https=) |
| KR (1) | KR20200047655A (https=) |
| CN (1) | CN111093652A (https=) |
| AU (1) | AU2018328131B2 (https=) |
| BR (1) | BR112020004429A2 (https=) |
| CA (1) | CA3074732A1 (https=) |
| IL (1) | IL272847B1 (https=) |
| MA (1) | MA50080A (https=) |
| MX (2) | MX2020002485A (https=) |
| SG (1) | SG11202001749SA (https=) |
| UA (1) | UA126688C2 (https=) |
| WO (1) | WO2019050923A1 (https=) |
| ZA (1) | ZA202001258B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022538608A (ja) * | 2019-06-28 | 2022-09-05 | ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア | アルツハイマー病の治療のための鼻腔内ダントロレン投与 |
| WO2023081873A1 (en) * | 2021-11-05 | 2023-05-11 | Quorum Innovations, Llc | Materials and methods for preventing or reducing toxicity to organophosphates and other toxic materials |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7758890B2 (en) * | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
| EP1603513B1 (en) * | 2003-03-04 | 2020-12-30 | Lyotropic Therapeutics, Inc. | Dantrolene compositions |
| WO2013040501A1 (en) * | 2011-09-16 | 2013-03-21 | Pharmathene, Inc. | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof |
| DK2925327T3 (da) * | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression |
-
2018
- 2018-09-05 UA UAA202002205A patent/UA126688C2/uk unknown
- 2018-09-05 BR BR112020004429-6A patent/BR112020004429A2/pt unknown
- 2018-09-05 JP JP2020512813A patent/JP2020532555A/ja active Pending
- 2018-09-05 MX MX2020002485A patent/MX2020002485A/es unknown
- 2018-09-05 US US16/644,281 patent/US20200383954A1/en not_active Abandoned
- 2018-09-05 WO PCT/US2018/049515 patent/WO2019050923A1/en not_active Ceased
- 2018-09-05 MA MA050080A patent/MA50080A/fr unknown
- 2018-09-05 KR KR1020207009450A patent/KR20200047655A/ko not_active Ceased
- 2018-09-05 EP EP18779490.4A patent/EP3678659B1/en active Active
- 2018-09-05 CA CA3074732A patent/CA3074732A1/en active Pending
- 2018-09-05 CN CN201880057290.XA patent/CN111093652A/zh active Pending
- 2018-09-05 AU AU2018328131A patent/AU2018328131B2/en active Active
- 2018-09-05 SG SG11202001749SA patent/SG11202001749SA/en unknown
-
2020
- 2020-02-23 IL IL272847A patent/IL272847B1/en unknown
- 2020-02-27 ZA ZA2020/01258A patent/ZA202001258B/en unknown
- 2020-03-04 MX MX2023012415A patent/MX2023012415A/es unknown
-
2021
- 2021-12-02 US US17/540,878 patent/US20220087980A1/en active Pending
-
2023
- 2023-01-27 JP JP2023010846A patent/JP2023055802A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023055802A (ja) | 2023-04-18 |
| EP3678659C0 (en) | 2025-12-17 |
| MX2020002485A (es) | 2020-07-20 |
| SG11202001749SA (en) | 2020-03-30 |
| BR112020004429A2 (pt) | 2020-10-20 |
| RU2020112318A (ru) | 2021-10-06 |
| NZ762056A (en) | 2025-10-31 |
| JP2020532555A (ja) | 2020-11-12 |
| AU2018328131B2 (en) | 2024-04-18 |
| US20200383954A1 (en) | 2020-12-10 |
| EP3678659A1 (en) | 2020-07-15 |
| UA126688C2 (uk) | 2023-01-11 |
| IL272847B1 (en) | 2026-03-01 |
| MX2023012415A (es) | 2023-11-01 |
| CA3074732A1 (en) | 2019-03-14 |
| US20220087980A1 (en) | 2022-03-24 |
| AU2018328131A1 (en) | 2020-03-12 |
| ZA202001258B (en) | 2023-10-25 |
| RU2020112318A3 (https=) | 2021-10-26 |
| EP3678659B1 (en) | 2025-12-17 |
| CN111093652A (zh) | 2020-05-01 |
| IL272847A (en) | 2020-04-30 |
| WO2019050923A1 (en) | 2019-03-14 |
| KR20200047655A (ko) | 2020-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4087305C0 (fr) | Sélection d'une tranche de réseau relative à une application | |
| EP3496666A4 (en) | DEVICES AND METHODS FOR TREATING HEART VALVE INSUFFICIENCIES | |
| EP3516455A4 (en) | MICROLITHOGRAPHIC MANUFACTURE OF STRUCTURES | |
| EP3452060A4 (en) | Combination therapy for cancer treatment | |
| SI3743406T1 (sl) | Modulatorji TMEM16A | |
| EP3446194A4 (en) | APPLICATION LINKS FOR CARPLAY | |
| EP3526328A4 (en) | COMBINATION THERAPY FOR C3 INHIBITION | |
| EP3504187A4 (en) | USE OF PRIDOPIDIN FOR THE TREATMENT OF FUNCTIONAL DECAY | |
| EP3416638A4 (en) | METHOD AND CONNECTIONS FOR RESTORING THE MUTANT P53 FUNCTION | |
| EP3383996A4 (en) | APPARATUS FOR SIMULATING A FUNCTION OF A LIVER AND METHOD FOR USE AND MANUFACTURE THEREOF | |
| EP3474842A4 (en) | COMPOSITIONS, DEVICES AND METHODS FOR TREATING ALKOHOL CONSUMPTION | |
| FI4327866T3 (fi) | Mirikitsumabi haavaisen paksusuolitulehduksen hoitoon | |
| MA46791A (fr) | Composés et procédés pour réduire l'expression d'atxn3 | |
| EP3411737A4 (en) | WAVEGUIDE INTERSECTION | |
| DK3891145T3 (da) | Modulatorer af trex1 | |
| EP3678675A4 (en) | NEW USE OF DEXTRAN SULFATE | |
| MA45492A (fr) | Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène | |
| EP3416645A4 (en) | COMPOUNDS FOR THE TREATMENT OF MALARIA | |
| EP3360377A4 (en) | Establishing a voice call | |
| EP3478284A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| MA45973A (fr) | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple | |
| MA50080A (fr) | Méthodes d'utilisation du dantrolène pour traiter l'exposition à un agent neurotoxique | |
| EP3568754C0 (en) | Temporarily suppressing processing of a restrained storage operand request | |
| EP3897650A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | |
| MA50119A (fr) | Découverte de règle de vecteur sémantique |